Analyzing VivoSim Labs (VIVS) and Its Competitors

Institutional & Insider Ownership

8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 51.0% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 3.7% of VivoSim Labs shares are owned by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares VivoSim Labs and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
VivoSim Labs	$140,000.00	-$2.48 million	-0.41
VivoSim Labs Competitors	$956.97 million	-$43.81 million	-0.62

VivoSim Labs’ peers have higher revenue, but lower earnings than VivoSim Labs. VivoSim Labs is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

VivoSim Labs has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, VivoSim Labs’ peers have a beta of 0.63, suggesting that their average share price is 37% less volatile than the S&P 500.

Profitability

This table compares VivoSim Labs and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-1,396.48%	-32.95%	-21.31%
VivoSim Labs Competitors	-1,418.91%	-632.07%	-29.27%

Summary

VivoSim Labs beats its peers on 6 of the 9 factors compared.

VivoSim Labs Company Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.